## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($342.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes**
- Source: Finviz | 20251222T150954 | Somewhat-Bullish | Relevance: 100%
- Citi adjusted its price target for Stryker Corporation (SYK) from $455 to $420 while maintaining a Buy rating, as part of a sector-wide evaluation for its 2026 outlook. Separately, Stryker declared a quarterly dividend of $0.88 per share, a 4.8% increase, and announced leadership changes with Spencer Stiles appointed President and COO, and Dylan Crotty promoted to Group President of Orthopaedics. The article also highlights Stryker's use of AI in medical technologies.

**2. Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes**
- Source: Insider Monkey | 20251222T095300 | Somewhat-Bullish | Relevance: 100%
- Citi cut the price target for Stryker Corporation (NYSE: SYK) from $455 to $420, while maintaining a Buy rating, as part of a sector-wide adjustment for its 2026 outlook. The company also declared a quarterly dividend of $0.88 per share, a 4.8% increase, and appointed Spencer Stiles as President and COO, alongside other leadership changes. Stryker, a medical technology firm, utilizes AI in various healthcare applications, though the article suggests other AI stocks might offer greater returns.

**3. CCLA Investment Management Has $141.98 Million Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251222T100952 | Somewhat-Bullish | Relevance: 100%
- CCLA Investment Management has increased its stake in Stryker Corporation (NYSE:SYK) by 10.1%, now holding 384,158 shares valued at $141.98 million, making it their 18th largest holding. Despite significant insider selling over the past 90 days, institutional investors own 77.09% of the company. Stryker also reported strong quarterly earnings, beating estimates, and increased its quarterly dividend.

**4. Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?**
- Source: Insider Monkey | 20251223T080500 | Neutral | Relevance: 64%
- Parnassus Investments initiated a position in Boston Scientific Corporation (NYSE:BSX) in the third quarter of 2025, viewing it as an innovative medical device maker with significant growth drivers. The company's first-mover advantage, robust clinical data, and strong physician relationships enable it to maintain dominant market share and outgrow competitors. Management's disciplined R&D and M&A strategies are driving organic sales growth and margin expansion, positioning Boston Scientific for durable growth amidst expanding margins and global demand tailwinds.

**5. Does Becton Dickinsonâ€™s Recent Slide Create an Opportunity for Long Term Investors in 2025?**
- Source: Simply Wall Street | 20251222T202011 | Neutral | Relevance: 63%
- Becton Dickinson (NYSE: BDX) has seen its stock price decline, leading some to question if it presents a value opportunity. A Discounted Cash Flow (DCF) analysis suggests it is undervalued by 39.7%, with an estimated intrinsic value of $324.56 per share compared to its current price of $195.59. However, its Price-to-Earnings (PE) ratio of 33.2x is slightly above the industry average, indicating it is reasonably valued based on current earnings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 5.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.7B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.7 |
| Current P/E | 26.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -1.1% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 44. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.07% (CS: 49) | Neutral |
| RSI_14 | 43.6 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 0.946x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $354.78
- **Stop Loss:** $342.14 (3.6% risk)
- **Target:** $367.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 94
- **Position Value:** $33,349.32
- **Portfolio %:** 33.35%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*